AUTL - Here's Why Autolus Therapeutics Is Surging Today
Shares of Autolus Therapeutics (NASDAQ: AUTL) , a clinical-stage biopharmaceutical company, are on the move after the company announced a new deal with Moderna (NASDAQ: MRNA) . Investors excited about Autolus Therapeutics' potential role in Moderna's commercialization of RNA-based therapeutics drove the stock more than 25% higher when the market opened, but the gains have subsided as investors pick apart the details. Autolus Therapeutics' stock price was 13% higher as of 11:18 a.m. EDT on Monday.
Autolus is developing a whole new class of reprogrammed T-cell therapies to treat cancer and not RNA-based drugs like Moderna. Under the terms of a new exclusive access agreement, though, Moderna could incorporate some of Autolus' proprietary binders into new cancer therapy candidates.
Image source: Getty Images.
For further details see:
Here's Why Autolus Therapeutics Is Surging Today